Immutep Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Immutep de 60.3% y 71.2% por año respectivamente. Se prevé que el BPA crezca en un 69.5% al año. Se espera que la rentabilidad financiera sea de -68.8% en 3 años.

Información clave

3.7%

Tasa de crecimiento de los beneficios

3.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	15.9%
Tasa de crecimiento de los ingresos	37.4%
Rentabilidad financiera futura	-85.3%
Cobertura de analistas	Good
Última actualización	07 Jun 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Is Immutep (ASX:IMM) Weighed On By Its Debt Load?

May 19

Previsiones de crecimiento de beneficios e ingresos

ASX:IMM - Estimaciones futuras de los analistas y datos financieros pasados (AUD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2026	11	-51	-63	-49	6
6/30/2025	15	-44	-72	-45	6
6/30/2024	4	-47	-47	-44	7
12/31/2023	4	-41	-42	-42	N/A
9/30/2023	4	-40	-39	-39	N/A
6/30/2023	4	-40	-35	-35	N/A
3/31/2023	4	-38	-33	-33	N/A
12/31/2022	4	-37	-30	-30	N/A
9/30/2022	5	-34	-30	-30	N/A
6/30/2022	5	-32	-30	-30	N/A
3/31/2022	4	-29	-25	-25	N/A
12/31/2021	4	-26	-20	-20	N/A
9/30/2021	4	-28	-19	-19	N/A
6/30/2021	4	-30	-18	-18	N/A
3/31/2021	5	-29	-16	-16	N/A
12/31/2020	6	-27	-15	-15	N/A
9/30/2020	10	-20	-13	-13	N/A
6/30/2020	14	-13	-11	-11	N/A
3/31/2020	13	-15	-13	-13	N/A
12/31/2019	13	-16	-14	-14	N/A
9/30/2019	9	-17	-15	-15	N/A
6/30/2019	6	-18	-15	-15	N/A
3/31/2019	5	-18	-13	-13	N/A
12/31/2018	5	-17	-10	-10	N/A
9/30/2018	6	-15	-9	-9	N/A
6/30/2018	7	-13	-8	-8	N/A
3/31/2018	6	-12	-8	-8	N/A
12/31/2017	7	-10	-8	-8	N/A
9/30/2017	5	-9	N/A	-8	N/A
6/30/2017	4	-9	N/A	-9	N/A
3/31/2017	3	-10	N/A	-8	N/A
12/31/2016	2	-10	N/A	-9	N/A
9/30/2016	2	-36	N/A	-10	N/A
6/30/2016	2	-62	N/A	-11	N/A
3/31/2016	2	-71	N/A	-10	N/A
12/31/2015	1	-82	N/A	-8	N/A
9/30/2015	1	-57	N/A	-8	N/A
6/30/2015	1	-32	N/A	-8	N/A
3/31/2015	1	-23	N/A	-10	N/A
12/31/2014	1	-14	N/A	-13	N/A
9/30/2014	2	-14	N/A	-13	N/A
6/30/2014	2	-13	N/A	-14	N/A
3/31/2014	2	-13	N/A	-14	N/A
12/31/2013	2	-13	N/A	-14	N/A
9/30/2013	2	-14	N/A	-15	N/A
6/30/2013	2	-15	N/A	-16	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que IMM siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que IMM siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que IMM siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (71.2% al año) de IMM crezcan más rápidamente que los del mercado Australian (4.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (71.2% al año) de IMM crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: IMM se prevé que no sea rentable en 3 años.

Immutep Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

No longer forecast to breakeven

Price target increased by 8.1% to AU$0.97

Price target decreased by 29% to AU$0.90

Consensus EPS estimates fall by 54%

Consensus EPS estimates upgraded to AU$0.024 loss

Consensus EPS estimates fall by 58%

Recent updates

No longer forecast to breakeven

Immutep Limited Announces Clinical Collaboration with Msd to Evaluate Efti in Combination with Keytruda®? (Pembrolizumab) in Pivotal Phase Iii Trial

Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024

Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Price target increased by 8.1% to AU$0.97

Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

New minor risk - Profitability

Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761

Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Price target decreased by 29% to AU$0.90

Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti

Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer

Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Consensus EPS estimates fall by 54%

Immutep Limited Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA(R) in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Immutep Announces New Biomarker Data from Tacti-002 Phase II in First Line Non-Small Cell Lung Cancer

Immutep Limited Reports Promising Clinical Data from Insight-003 Trial at ESMO Congress 2023

Consensus EPS estimates upgraded to AU$0.024 loss

Immutep Limited Announces Excellent New Clinical Data from the TACTI-002 / KEYNOTE-798 Phase II Trial Evaluating Eftilagimod Alpha

Immutep Limited Announces Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

Consensus EPS estimates fall by 58%

Immutep Limited, Annual General Meeting, Oct 24, 2023

Consensus revenue estimates decrease by 77%, EPS upgraded

Full year 2023 earnings: EPS and revenues miss analyst expectations

Immutep Limited Receives Positive Scientific Advice from Committee for Medicinal Products for Human Use of European Medicines Agency for Continued Development of Eftilagimod Alpha

Immutep Limited Announces First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

Forecast to breakeven in 2026

Consensus EPS estimates upgraded to AU$0.052 loss

Immutep Limited Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer

Immutep Limited Announces Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer

Consensus EPS estimates fall by 23%

Immutep Limited Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

Consensus revenue estimates increase by 19%

Price target increased by 15% to AU$1.33

No longer forecast to breakeven

Consensus revenue estimates increase by 20%

First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.019 loss in 1H 2022)

Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC

Immutep Limited Announces Update on INSIGHT-003 Trial in NSCLC

Consensus forecasts updated

Immutep Limited Enrolls and Randomised over 50% of the Planned 154 Patients in the Tacti-003 Phase IIB Trial

Immutep Limited Announces the Results of Positive Follow-Up Type C Meeting with the US Food and Drug Administration

Immutep Limited Announces the Successful Scale-Up of the Manufacturing of its Lead Product Candidate Eftilagimod Alpha

Immutep Limited Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease

Less than half of directors are independent

Consensus forecasts updated

Immutep Limited Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting

Immutep Limited Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned

Immutep Limited Announces the United States Food and Drug Administration (Fda) Has Granted Fast Track Designation to Eftilagimod Alpha

Consensus forecasts updated

Immutep Limited, Annual General Meeting, Nov 23, 2022

Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Immutep Appoints Frederic Triebel as Executive Director

Immutep Limited Announces Investigator-Initiated Phase Ii Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

Immutep Limited Announces Investigator-Initiated Phase Ii Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

No longer forecast to breakeven

Immutep Limited Grants Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor

Immutep Limited Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLC

Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates, eftilagimod alpha and IMP76 for the Quarter Ended 30 June 2022

Forecast to breakeven in 2025

Immutep Limited Reports Positive Overall Response Rate in Its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers

High number of new and inexperienced directors

Is Immutep (ASX:IMM) Weighed On By Its Debt Load?

Immutep Limited Announces Executive Changes

Immutep Limited Presents New and Significant Data from the AIPAC Study

Immutep Limited Provides Update on the Ongoing Development of Its Product Candidates, Eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2022

Price target decreased to AU$1.07

Immutep’S Efti in Combination with Msd’S Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2Nd Line Metastatic Lung Cancer Patients